CClinicalTrials.gg
CompletedNCT06083506Updated Jul 20, 2025Results posted

Immediate Loading of 4 Guided Implants Supporting a Maxillary Overdenture Using a Novaloc TiN Retention System

An interventional study of NOVALOC TiN retained maxillary overdenture in Immediate Dental Implant Loading and Denture, Complete, sponsored by West Virginia University. Completed at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-20.

Sponsored by West Virginia University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 9 months after the study started (first participant enrolled Jan 2019, registered Oct 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Study summary

Complete dentures represent the traditional dental treatment for patients without teeth. However, retention and stability of this type of denture are often lacking, so dental implants are indicated in order to improve the stability of the denture, along with the satisfaction of the patient. Usually, the dental implants are inserted and then a period of 3-6 months is waited before any denture is connected to them. Recent studies have demonstrated that connecting the lower denture to the implants immediately after the implant placement, leads to an improvement in the result, with a social and psychological benefit for the patient. Therefore, the aim of this research project is to evaluate the application of the immediate connections of the implants for the upper dentures. 15-40 patients wearing an upper denture will receive 4 dental implants and the denture will be immediately connected. To simplify the surgical procedure, the implants will be placed without exposing the bone. This surgical technique is called guided surgery. Secondary objective of this research project will be the evaluation of the precision of the implant positioning, using this specific technique. The patients will be followed up for 12 months, for the implant and denture evaluation, as well as the evaluation of patient satisfaction and impact on quality of life through questionnaires.

02

Conditions studied

  • Immediate Dental Implant Loading
  • Denture, Complete
03

In context

Lead sponsor

West Virginia University is the lead sponsor of 155 studies on the registry; 35 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Fully edentulous maxilla
  • The implant site has to be healed for at least 4 months after extraction
  • Wearing complete dentures deemed adequate
  • Orthopantomogram available (OPT)
  • Adequate amount of bone at least at the 2nd premolar position to house a 3.75 x 10 mm implant
  • No bone grafting required
  • Implant IT ≥ 20 N/cm

Exclusion criteria

Exclusion Criteria:

  • Conditions requiring chronic routine prophylactic use of antibiotics
  • Conditions requiring prolonged use of steroids
  • History of leukocyte dysfunction and deficiencies
  • Bleeding disorders
  • History of neoplastic disease requiring use of radiation or chemotherapy
  • Metabolic bone disorders
  • Uncontrolled endocrine disorder
  • Use of any investigational drug or device within the 30-day period prior to implant surgery
  • Smoking more than 10 cigarettes a day
  • Alcoholism or drug abuse
  • Patient infected with HIV
  • Condition or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, unreliability.

Local exclusion criteria:

  • Local inflammation including untreated periodontitis
  • Mucosal disease such as erosive lichen planus
  • History of local irradiation therapy
  • Osseous lesion
  • Severe bruxism and clenching habits
  • Active infection with suppuration or fistula track
  • Persistent intraoral infection
  • Lack of primary stability \<20Ncm. In this instance, the patient must be withdrawn and treated according to the standard protocol.
  • Inadequate oral hygiene or unmotivated home care.
  • Bone grafting
  • Inadequate bone volume for implants insertion as measured on the per-treatment CBCT.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Other
    NOVALOC TiN

    Each subject will receive 4 implants. Implants will be placed flapless using a guided surgical protocol and will be immediately loaded by means of a NOVALOC TiN retained maxillary overdenture.

    Device: NOVALOC TiN retained maxillary overdenture

Interventions

  • DeviceNOVALOC TiN retained maxillary overdenture

    4 implants immediately loaded by means of a NOVALOC TiN retained maxillary overdenture

06

What researchers measure

Primary outcomes

  1. Radiographic Bone Level (RBL) Change

    RBL change will be measured in mm on standardized periapical radiographs. The distance between the implant platform and the most coronal level of the bone deemed to be in contact with the implant surface will be evaluated. Mesial and distal bone height measurements will be averaged for each implant. The measurements of the bone level at implant placement will be considered as baseline. The RBL change will be calculated in comparison with the baseline value.

    Time frame: Baseline to 6 months post implant

  2. Radiographic Bone Level (RBL) Change

    RBL change will be measured in mm on standardized periapical radiographs. The distance between the implant platform and the most coronal level of the bone deemed to be in contact with the implant surface will be evaluated. Mesial and distal bone height measurements will be averaged for each implant. The measurements of the bone level at implant placement will be considered as baseline. The RBL change will be calculated in comparison with the baseline value.

    Time frame: Baseline to 12 months post implant

07

Results

Posted Jul 20, 2025

Participant flow

Participant flow — Overall Study
MilestoneNOVALOC TiN
Started17
Completed14
Not completed3
Withdrew: Physician decision2
Withdrew: Lack of efficacy1

Outcome measures

PrimaryRadiographic Bone Level (RBL) Change

RBL change will be measured in mm on standardized periapical radiographs. The distance between the implant platform and the most coronal level of the bone deemed to be in contact with the implant surface will be evaluated. Mesial and distal bone height measurements will be averaged for each implant. The measurements of the bone level at implant placement will be considered as baseline. The RBL change will be calculated in comparison with the baseline value.

Time frame:
Baseline to 6 months post implant
Reported as:
Mean · millimeters (mm)
Radiographic Bone Level (RBL) Change
millimeters (mm)NOVALOC TiN
Radiographic Bone Level (RBL) Change0.14 ± 0.36
PrimaryRadiographic Bone Level (RBL) Change

RBL change will be measured in mm on standardized periapical radiographs. The distance between the implant platform and the most coronal level of the bone deemed to be in contact with the implant surface will be evaluated. Mesial and distal bone height measurements will be averaged for each implant. The measurements of the bone level at implant placement will be considered as baseline. The RBL change will be calculated in comparison with the baseline value.

Time frame:
Baseline to 12 months post implant
Reported as:
Mean · millimeters (mm)
Radiographic Bone Level (RBL) Change
millimeters (mm)NOVALOC TiN
Radiographic Bone Level (RBL) Change0.31 ± 0.73

Adverse events

Collected over 12 Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NOVALOC TiN0/14 (0%)0/14 (0%)0/14 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)NOVALOC TiN
Mean64.2 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)NOVALOC TiN
Female2
Male12
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)NOVALOC TiN
Diabetics
Diabetics(Participants)NOVALOC TiN
Count of participants4
Tobacco Use Status
Tobacco Use Status(Participants)NOVALOC TiN
Count of participants1
08

Study locations

1 site
  • West Virginia University
    Morgantown, West Virginia 26506, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Dec 15, 2021
  • Informed consent form · Dec 15, 2021

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06083506
Lead sponsor
West Virginia University
Collaborators
Institut Straumann AG
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Jan 3, 2019
Primary completion
May 15, 2023
Completion
May 15, 2023
Results posted
Jul 20, 2025
Last update
Jul 20, 2025

Study contacts

Arif Salman, BDS, MDSc
principal investigator · West Virginia University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion